HGEN - Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Humanigen (HGEN) has completed enrollment for its Phase 3 study of lenzilumab for COVID-19. Top-line data expected in March 2021. The primary objective of this trial, which enrolled 520 patients, is to determine whether lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome and improve ventilator-free survival in hospitalized and hypoxic patients with COVID-19 pneumonia.The company has teamed with many other companies and U.S. government for the advancement of lenzilumab.Shares up 9% premarket.

For further details see:

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19